This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D66 (hereditary factor VIII deficiency) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Hemophilia A, congenital coagulation factor VIII deficiency, antihemophilic factor deficiency (AHF deficiency), Classical hemophilia, Hemophilia A, Congenital factor VIII deficiency, Factor VIII:C deficiency |
| C. Adult onset | Possibility of first onset in adulthood: not low — in mild (FVIII 5–40%) patients, who account for about 30–45% of the total, it is common for abnormal bleeding to be first recognized and diagnosed after age 18 in the absence of clear triggers such as surgery, tooth extraction, or trauma; some moderate cases (FVIII 1–5%) can also be first diagnosed in adulthood; severe cases (FVIII < 1%) have frequent spontaneous bleeding and are mostly diagnosed in infancy and childhood. |
| 1. History | First record in the Talmud (5th century) → 1803 first clinical description by Otto → 1937 Patek and Taylor isolate antihemophilic factor → 1964 Pool discovers cryoprecipitate → 1984 F8 gene cloning → 1992 recombinant FVIII launched → 2017 emicizumab approved → 2022 gene therapy approved. |
| 2. Causes | X-linked recessive inheritance. Defective FVIII synthesis and function due to F8 gene mutations. Intron 22 inversion (about 45–50% of severe cases), intron 1 inversion (5%), point mutations, deletions, insertions, etc. About 30% arise from new mutations without family history. |
| 3. Genetics | F8 gene: long arm of the X chromosome (Xq28), 186 kb, 26 exons. A 2332-amino-acid protein (A1-A2-B-A3-C1-C2 domains). Circulates bound to vWF. Female carriers have a 50% probability of giving birth to an affected boy. Severity classified by FVIII activity (< 1%, 1–5%, 5–40%). |
| 4. General epidemiology | About 1 in 5,000–10,000 male births. Accounts for about 80% of all hemophilia. An estimated 400,000 affected worldwide. Korean hemophilia registry (KBDR): 2,120 with type A, 66% severe. Occurs regardless of ethnicity or region. Acquired hemophilia A is a separate disease caused by autoantibodies. |
| 5. Pathophysiology | FVIII is the key cofactor of the intrinsic coagulation pathway tenase complex (FIXa·FVIIIa·Ca²⁺·phospholipid). Deficiency → insufficient FX activation → decreased thrombin generation → poor clot formation. Recurrent intra-articular bleeding → synovial iron deposition and chronic inflammation → hemophilic arthropathy. |
| 6. Symptoms | Severe: spontaneous, recurrent hemarthrosis (knees, elbows, ankles), muscle hematoma (iliopsoas), intracranial hemorrhage. Moderate: excessive bleeding after trauma, rare spontaneous bleeding. Mild: delayed hemostasis with trauma, surgery, or tooth extraction. Newborns: intracranial hemorrhage, excessive bleeding after circumcision. |
| 7. Signs | Joint swelling, warmth, limited motion. Synovitis, joint stiffness, and muscle atrophy after recurrent hemarthrosis. Formation of target joints. Isolated APTT prolongation; normal PT, TT, and platelets. Decreased FVIII activity. Resistance to treatment when inhibitor positive. |
| 8. Screening | No screening of the general population. Newborns with family history: cord blood FVIII activity measurement. Confirmation of female carriers: molecular genetics (F8 gene analysis). Prenatal diagnosis: chorionic villus sampling (11–14 weeks) or amniocentesis (15–20 weeks). Preimplantation genetic testing (PGT) possible. |
| 9. Diagnosis | Screening: APTT prolongation. Confirmation: FVIII activity measurement (one-stage, two-stage chromogenic substrate method). Exclude vWD with vWF tests. Inhibitors: Bethesda assay. Genetic testing: intron 22 and 1 inversion analysis, next-generation sequencing (NGS). Joint imaging: X-ray, MRI, ultrasound. |
| 10. Treatment | FVIII concentrates (plasma-derived or recombinant, standard or extended half-life) as prophylaxis or on demand. Mild: DDAVP. Emicizumab (subcutaneous injection, with or without inhibitors). Fitusiran (antithrombin RNAi, 2025 FDA approval). Valoctocogene roxaparvovec (gene therapy). Patients with inhibitors: ITI or bypassing therapy. |
| 11. Prognosis | Life expectancy nearly normal with modern prophylaxis. Major prognostic factors: inhibitor development (about 25–30% of severe cases), hemophilic arthropathy, past HIV and HCV infection. Joint damage can be prevented with early primary prophylaxis. Gene therapy offers the possibility of long-term elimination of bleeding. |
| 12. Prevention | Primary: genetic testing and genetic counseling, preimplantation genetic testing (PGT). Secondary: early primary prophylaxis (severe patients, before first bleed or joint damage). Tertiary: rehabilitation and physical therapy, NSAID avoidance, FVIII replacement before invasive procedures, individual bleeding emergency plans. |
| 13. References | World Federation of Hemophilia. Guidelines for the Management of Haemophilia, 3rd edition, 2020 … and 9 other papers |
The history of hemophilia began together with human civilization. The oldest record is the Babylonian Talmud from around the 5th century AD, which states that if a boy died of bleeding after circumcision, the next brother was exempted from circumcision. This is regarded as the first clinical record that intuitively grasped the X-linked mode of inheritance. In the 10th century, the Arab physician Al-Zahrawi described families with a bleeding tendency appearing only in males.
The starting point of modern hemophilia science is the 1803 paper in which the American physician John Conrad Otto described in detail a family with a hemorrhagic diathesis. Otto clearly pointed out that this disease manifests only in males and is transmitted through mothers. In 1820, Christian Friedrich Nasse of Germany presented 'Nasse's law' (X-linked recessive inheritance), laying the theoretical foundation for the mode of inheritance. In 1828, Hopff first used the term 'Haemophilia'.
In the early 20th century, understanding of the pathophysiology and molecular basis advanced rapidly. In 1911, Schmidt of Germany demonstrated that blood clotting time is prolonged, and in 1937 Arthur Patek and Frank Taylor isolated 'antihemophilic factor (AHF)' from plasma. In 1947, Alfredo Pavlovsky of Argentina suggested the existence of two forms of hemophilia through an experiment showing that mixing the plasma of two hemophilia patients corrected clotting, and in 1952 Rosemary Biggs et al. of the UK identified these as deficiencies of factor VIII (hemophilia A) and factor IX (hemophilia B, Christmas disease), respectively.
The biggest turning point in the history of treatment was the discovery of cryoprecipitate by Judith Graham Pool of the United States in 1964. She discovered that slowly thawing fresh frozen plasma (FFP) forms a precipitate layer concentrated in factor VIII, making it possible for the first time to systematically supply large amounts of FVIII. After 1968, FVIII concentrates made by plasma pooling were developed, enabling self-injection and greatly improving the social participation of hemophilia patients. However, in the 1970s–1980s, non-virus-inactivated plasma-derived products led to a tragic iatrogenic infection disaster in which hundreds of thousands of hemophilia patients were infected with HIV and hepatitis C virus (HCV).
In 1984, Wood et al. and Toole et al. independently succeeded in cloning the entire F8 gene, opening the way for recombinant technology. In 1989, the non-viral inactivation process was standardized, and in 1992 the US FDA approved recombinant FVIII (Recombinate, Baxter), bringing treatment free of infection risk into full swing. In the 2000s, extended half-life (EHL) products were developed, enabling prophylaxis to be maintained with injections 1–2 times per week. In 2017, the innovative bispecific antibody emicizumab (Hemlibra) was approved by the FDA for patients with inhibitors, and in 2018 its indication was expanded to patients without inhibitors. In 2022, the gene therapy valoctocogene roxaparvovec (Roctavian) was first approved by the FDA for adult severe hemophilia A, and in March 2025 fitusiran (Qfitlia) received FDA approval as an RNAi therapy with an antithrombin-inhibiting mechanism.
The history of hemophilia treatment in Korea began with the introduction of cryoprecipitate in the 1970s and developed through the supply of plasma-derived FVIII concentrates in the 1980s–90s, the expansion of recombinant products and application of prophylaxis in the 2000s, and the introduction of extended half-life products and emicizumab in the 2010s. Patient support centered on the Korea Hemophilia Foundation and expanded National Health Insurance coverage have contributed to improved access to treatment, and the Korean Bleeding Disorder Registry (KBDR) plays an important role in understanding domestic epidemiology and clinical status.
Hereditary factor VIII deficiency (hemophilia A) is an X-linked recessive genetic disease caused by pathogenic variants in the F8 gene located on the long arm of the X chromosome (Xq28), resulting in decreased synthesis or impaired function of blood coagulation factor VIII (FVIII). The F8 gene, with a total length of 186 kb, is one of the largest genes in the human genome and consists of 26 exons and 25 introns.
F8 gene variants are broadly divided into structural variants and small variants. The most common and important variant is the intron 22 inversion, which accounts for about 45–50% of severe hemophilia A. This inversion results from intrachromosomal homologous recombination between a 9.6 kb repeat sequence (int22h-1) in intron 22 of the F8 gene and two inversely oriented identical sequences (int22h-2, int22h-3) located 300 kb upstream of the F8 gene. This inversion splits the F8 gene into two pieces, with exons 1–22 and exons 23–26 placed in opposite orientations, making transcription of the full mRNA that produces normal FVIII protein impossible. The intron 1 inversion accounts for about 5% of severe hemophilia A and arises from inverse recombination of repeat sequences within intron 1.
Other small variants include point mutations (missense, nonsense), deletions, insertions, and splice-site variants. Large exon deletions or nonsense mutations are usually associated with a severe phenotype, and missense mutations with a moderate or mild phenotype. Even among missense variants, the effects on FVIII protein synthesis, secretion, vWF binding, and coagulation cofactor activity differ depending on the domain location and type of amino acid change.
About 30% of hemophilia A patients have no family history, which is due to new (de novo) mutations arising at the germ cell stage of the mother (or maternal grandmother, maternal great-grandmother). New mutations occur particularly frequently in the intron 22 inversion, which is explained by the structural characteristics of this region promoting homologous recombination.
The mode of inheritance is X-linked recessive. Because males have only one X chromosome, the disease manifests if there is an F8 gene variant. Females with a variant on one of their two X chromosomes are usually asymptomatic carriers, but depending on random inactivation of the normal X chromosome (lyonization), FVIII activity may also decrease in some carrier women, who may show bleeding symptoms. In women with variants on both X chromosomes (homozygous or compound heterozygous), severe hemophilia similar to that in males manifests.
The F8 gene is located at the distal end of the long arm of the X chromosome (Xq28), and with a total size of 186 kb is one of the largest genes in the human genome. The mRNA, composed of 26 exons, is 9 kb, the precursor protein (prepropeptide) translated from it is 2,351 amino acids, and after signal peptide cleavage mature FVIII consists of 2,332 amino acids. The protein structure of FVIII has a domain arrangement of A1-A2-B-A3-C1-C2, and each domain is functionally specialized. The A1 and A2 domains are involved in copper binding, the A3, C1, and C2 domains in phospholipid binding and binding with von Willebrand factor (vWF), and the large B domain is released after proteolytic processing.
In the blood, FVIII circulates mainly in a noncovalent complex with vWF, and this binding protects FVIII from proteolytic enzymes and renal clearance. When activated thrombin (IIa) or factor Xa cleaves FVIII and activates it to FVIIIa, it is released from vWF and forms the tenase complex with FIXa on the phospholipid surface. This complex is responsible for the catalytic function of activating FX to FXa.
The association between mutation type and severity is quite clear. Severe (FVIII < 1%): mostly intron 22 and 1 inversions, large deletions, nonsense variants. Moderate (FVIII 1–5%): splicing variants, some small deletions and insertions, some missense variants. Mild (FVIII 5–40%): mainly missense variants. Individual differences exist even within the same severity, because genetic background (modifier genes) and immune reactivity to the FVIII protein have an influence.
Genetic risk factors for inhibitor development also require attention. In about 25–30% of patients with severe hemophilia A, neutralizing antibodies (inhibitors) develop after FVIII infusion, which is the greatest complication of treatment. Genetic factors associated with inhibitor development that have been reported include the F8 variant type (higher risk with large deletions and nonsense variants), HLA type as a non-genotype factor, IL-10 and CTLA4 polymorphisms, and TNF-α genotype. Patients with the intron 22 inversion have a relatively high inhibitor incidence of about 20–25%.
Molecular genetic testing for carrier determination and prenatal diagnosis has been standardized in clinical practice. When an F8 variant has been identified in the family, linkage analysis or direct variant detection methods are used. In families with an unidentified variant, indirect linkage analysis using polymorphic markers is possible. Prenatal diagnosis analyzes fetal DNA collected by chorionic villus sampling (CVS, 11–14 weeks of pregnancy) or amniocentesis (15–20 weeks of pregnancy), and preimplantation genetic testing (PGT) is performed in some countries together with in vitro fertilization as a method of preventing implantation of an affected embryo. NGS-based whole F8 gene analysis has become established as the standard for variant detection, and molecular confirmation is essential for clinical management, genetic counseling, and evaluation of eligibility for new treatments (gene therapy).
Hereditary factor VIII deficiency (hemophilia A) is a rare bleeding disorder occurring in all ethnic groups and regions worldwide, with a frequency of about 1 in 5,000–10,000 male births. According to the 2023 annual report of the World Federation of Hemophilia (WFH), about 828,000 hemophilia patients (including types A and B) are registered worldwide, and the actual number of patients is estimated at about 1.1–1.2 million. Because hemophilia A accounts for about 80–85% of all hemophilia, the number of hemophilia A patients worldwide is estimated at about 400,000–450,000.
The severity distribution worldwide is reported as about 40–50% severe (FVIII < 1%), about 10–15% moderate (FVIII 1–5%), and about 30–45% mild (FVIII 5–40%). However, in countries with low diagnostic access, many mild patients are undiagnosed, so the proportion of severe cases is counted relatively high. In principle hemophilia A manifests biologically only in males (X-linked recessive), but in rare cases it can also manifest in females due to homozygous variants, Turner syndrome (45,X), or unequal X inactivation. Acquired hemophilia A is a separate disease caused by the development of autoantibodies against FVIII; it occurs equally in men and women and is observed mainly in the elderly population and pregnant women.
Epidemiology in Korea: According to Korean Bleeding Disorder Registry (KBDR) and Health Insurance Review & Assessment Service data, hemophilia A has 2,120 registered patients in Korea (as of 2022), accounting for about 73% of all registered hemophilia (types A+B). Severe cases account for about 66% of the total, and the annual bleeding-related hospitalization rate for severe cases shows a clearly decreasing trend after the implementation of prophylaxis. The mean age at diagnosis is most often within the first year of life for severe cases, while mild cases are sometimes first diagnosed at school age or in adulthood. In Korea, hemophilia A is designated as a 'rare disease' and 'ultra-rare disease', and upon Special Copayment Reduction (V009) registration a reduced copayment rate of 10% (5 years) is provided.
Because about 30% arise from new mutations, hemophilia must be included in the differential diagnosis of first bleeding episodes in the neonatal and infant period even when there is no family history. Because it occurs at the same frequency worldwide regardless of race or ethnicity, care is needed not to neglect diagnosis in migrant populations as well. The WFH estimates that about 75% of hemophilia patients worldwide do not receive adequate treatment, reflecting problems of medical access in low- and middle-income countries. In Korea, access to treatment is relatively good thanks to expanded National Health Insurance coverage and support from the Korea Hemophilia Foundation, but establishing coverage criteria for the latest therapies such as gene therapy remains a challenge.
In normal hemostasis, when tissue factor (TF) is exposed after vascular injury, a small amount of initial thrombin is generated through the extrinsic pathway. This thrombin activates platelets and activates FVIII to FVIIIa and FV to FVa, initiating the amplification phase. In the subsequent propagation phase, the intrinsic tenase complex is assembled on the phospholipid membrane of the activated platelet surface. This complex consists of FIXa (activated factor IX), FVIIIa (activated factor VIII), Ca²⁺ ions, and anionic phospholipids (mainly phosphatidylserine), and accelerates the rate of conversion of the substrate FX to FXa by about 100,000-fold or more compared with the absence of FVIII.
In hemophilia A, when FVIII activity is decreased or lost, the efficiency of the intrinsic tenase complex drops sharply, and the activity of FXa and the prothrombinase complex (FXa·FVa·Ca²⁺·phospholipid) decreases, so sufficient thrombin generation does not occur. As a result, the fibrin clot formed is insufficient, hemostasis is not achieved after trauma or surgery, and in severe patients spontaneous bleeding occurs. In severe patients with FVIII activity below 1%, the tenase complex is virtually nonfunctional, and in mild patients at 5–40%, hemostatic failure occurs only in 'challenging situations' such as trauma or surgery.
Mechanism of hemophilic joint damage: When hemarthrosis recurs, iron (heme iron) released from red blood cells in intra-articular blood is deposited in the synovium. Iron activates synoviocytes and generates reactive oxygen species (ROS) through iron-catalyzed oxidation reactions (Fenton reaction), damaging chondrocytes and the synovium. At the same time, inflammatory cytokines such as VEGF, IL-1β, and TNF-α are secreted, promoting abnormal proliferation of synoviocytes (pannus formation), angiogenesis, and secretion of cartilage-degrading enzymes (MMPs). When this vicious cycle continues, hemophilic arthropathy is established, progressing from chronic synovitis to cartilage destruction, subchondral bone damage, joint stiffness, and muscle atrophy. A target joint is one in which 3 or more bleeds in the same joint occur within 12 months; in this joint, synoviocyte proliferation and vascular proliferation are prominent, so rebleeding recurs even with minor stimulation.
Mechanism of FVIII inhibitor development: When exogenous FVIII is injected intravenously, antigen-presenting cells (APCs) present FVIII peptides on MHC II molecules, and CD4+ T helper cells and B cells are activated to produce FVIII-neutralizing antibodies (inhibitors), mainly of the IgG4 subclass. Inhibitors bind to functional sites of FVIII (especially the A2 and C2 domains) and neutralize its activity, so even high-dose FVIII injections lose their effect. Immune tolerance induction (ITI) therapy works through a mechanism of exhausting and inactivating inhibitor-specific B cell clones by administering high-dose FVIII over a long period. Non-factor therapies (emicizumab, fitusiran, etc.) bypass the FVIII coagulation pathway and so are not affected by inhibitors.
The clinical symptoms of hemophilia A are closely related to the FVIII activity level (severity), and the timing of onset and pattern of bleeding differ greatly by severity. In general, the lower the FVIII activity, the more severe and frequent the bleeding.
Symptoms of severe disease (FVIII < 1%): The most characteristic bleeding site is the joint, and hemarthrosis is the hallmark symptom of severe hemophilia A. The knees, elbows, and ankles are most frequently affected, and the hips, shoulders, and wrists are also involved. Hemarthrosis often begins with prodromal symptoms called an 'aura' before bleeding—warmth, tingling, limited joint motion. Severe patients who do not receive sufficient prophylaxis experience 20–40 spontaneous bleeds per year, and when blood collects in the joint, the joint swells and pain becomes extreme. Muscle hematomas are also common; in particular, iliopsoas hematoma causes abdominal, inguinal, and medial thigh pain and a flexed posture, and can cause femoral nerve palsy through nerve compression, requiring immediate recognition and treatment. Intracranial hemorrhage (ICH) is rare but the most dangerous complication and a major cause of death in inadequately treated patients.
Symptoms of moderate disease (FVIII 1–5%): Spontaneous bleeding is rare, and excessive bleeding after trauma or minor impact is characteristic. It appears as persistent or recurrent bleeding after surgery, tooth extraction, or bruising. Hemarthrosis is less frequent than in severe disease but not entirely absent.
Symptoms of mild disease (FVIII 5–40%): Abnormal bleeding appears only with serious trauma or invasive procedures such as surgery or tooth extraction. In some cases, diagnosis is not made until adulthood. Recurrent hemarthrosis is rare, so joint damage is relatively limited.
Symptoms in the neonatal and infant period: Characteristic features are intracranial hemorrhage (especially at or shortly after birth), excessive bleeding after circumcision, muscle hematoma after vaccination, and recurrent bruising when starting to crawl or walk. In patients with new mutations and no family history, the disease is sometimes first diagnosed through neonatal intracranial hemorrhage.
Mucosal bleeding: Mucosal bleeding such as gingival bleeding, epistaxis, hematuria, and gastrointestinal bleeding can also occur. In hemophilia A, nosebleeds are not as prominent as in platelet disorders, but they can be recurrent and prolonged.
Symptoms in patients with inhibitors: When an inhibitor develops, there is no response to standard FVIII administration, and bleeding may persist and become more severe. If bleeding increases despite existing prophylaxis or treatment response suddenly declines, inhibitor development should be suspected.
The physical signs of hemophilia A vary depending on the patient's severity, whether prophylaxis is given, and the duration of the disease. In patients who have received appropriate prophylaxis, physical signs may be mild or absent, whereas in patients with delayed diagnosis or insufficient treatment, signs of multiple musculoskeletal complications are evident.
Signs of acute hemarthrosis: Swelling, warmth, spontaneous pain and tenderness on palpation, and limited range of motion of the affected joint are characteristic. In the knee, increased popliteal fullness and ballottement of the patella may be observed. The joint assumes a flexed position (antalgic posture), and weight-bearing is refused. The skin may show discoloration from the early stage of bleeding (hemosiderin deposition from blood breakdown products). Acute hemarthrosis must be differentiated from local infection (septic arthritis), which is accompanied by fever and systemic symptoms.
Signs of chronic hemophilic arthropathy: In patients who have experienced recurrent hemarthrosis, joint deformity, flexion contracture, joint stiffness, muscle atrophy, leg length discrepancy (overgrowth or undergrowth during growth), and gait abnormalities appear. Synovial thickening due to synoviocyte proliferation is palpated as a soft, spongy (boggy) texture of the joint. The Hemophilia Joint Health Score (HJHS) is used as the standard for assessing chronic arthropathy. Knee X-rays show narrowed joint space, osteophytes, subchondral cysts, osteoporosis, and so on.
Target joint: The criterion is 3 or more bleeds in the same joint within 12 months, and on palpation this joint shows an elastic thickening due to synoviocyte proliferation. Ultrasound is useful for noninvasively assessing synovial thickness, angiogenesis, and joint effusion, and MRI is used for quantitative assessment of cartilage and bone structural damage.
Signs of muscle hematoma: Iliopsoas hematoma is characterized by abdominal and inguinal tenderness, a flexed hip posture, and pain on femoral nerve stretch (femoral stretch sign). When Volkmann ischemic contracture develops after forearm hematoma, finger flexion contracture, intrinsic muscle atrophy, and wrist flexion deformity are observed. When compartment syndrome is suspected, immediate FVIII administration and surgical evaluation are needed.
Laboratory findings: The activated partial thromboplastin time (APTT) is prolonged, and the prothrombin time (PT), thrombin time (TT), platelet count, and bleeding time are normal. Severity is confirmed by FVIII activity measurement; in the presence of an inhibitor, poor correction is seen on the APTT mixing study, and it is quantified by the Bethesda assay. Elevated serum iron and ferritin and elevated erythrocyte sedimentation rate (ESR) may appear when chronic arthropathy or synovitis is present.
Population-wide screening of the general population for hereditary factor VIII deficiency (hemophilia A) is not currently performed. This is because, with X-linked inheritance, the target population (boys who may be affected) is limited, and an effective, cost-efficient strategy for early diagnosis can be achieved even when centered on family history. However, systematic screening of at-risk groups and carrier testing of pregnant women play a key role in modern hemophilia management.
Screening of newborns and infants with a family history: When the mother is a carrier or the father is a hemophilia patient, FVIII activity is measured in cord blood or peripheral blood right after birth in boys born. The normal FVIII range in newborns is similar to that of adults (50–150 IU/dL), so measurement is possible. However, the physiological phenomenon of a transient rise in vWF levels right after birth must be considered, and ambiguous results are confirmed by remeasurement a few weeks later. In severe patients, FVIII deficiency is clearly apparent even on the day of birth, which is advantageous for early diagnosis and preparation for prophylaxis. Patients with new mutations and no family history are diagnosed at their first bleeding episode (intracranial hemorrhage, bleeding after circumcision, hematoma after vaccination, etc.), so clinical suspicion is important.
Female carrier testing: Mothers, daughters, and sisters of hemophilia patients may be carriers, and carriers may also have low FVIII activity and be at risk of bleeding. Molecular genetic F8 gene analysis is the standard for carrier confirmation, and when a variant has been identified in the family, direct variant detection methods (intron 22 and 1 inversion analysis, targeted variant analysis, NGS) are used. Phenotypic tests (plasma FVIII activity, vWF antigen) alone cannot exclude carrier status, and particularly when X inactivation is skewed, a woman may be a variant carrier even if FVIII activity is within the normal range. If a carrier woman's FVIII activity is below 40 IU/dL, there is a risk of bleeding during surgery or delivery, and a management plan needs to be established.
Prenatal diagnosis: In carrier pregnant women, if the fetus is male, F8 gene variants are analyzed in fetal DNA collected by chorionic villus sampling (CVS) at 11–14 weeks of pregnancy or by amniocentesis at 15–20 weeks of pregnancy. A method is also used of determining sex in early pregnancy through fetal RHD or SRY analysis and proceeding with invasive prenatal diagnosis only in male pregnancies. Preimplantation genetic testing (PGT) aims to select out affected embryos and implant unaffected embryos during in vitro fertilization, and is performed in some countries and institutions as a method allowing prevention without termination of pregnancy. Noninvasive prenatal testing (NIPT) technology using cell-free fetal DNA (cffDNA) in maternal plasma is at the research stage, but its clinical application to hemophilia has not yet been standardized.
Newborn screening and APTT: Some countries perform coagulation panel tests including APTT as part of screening for bleeding diathesis in newborns, but APTT alone has low specificity, so its role as universal newborn screening is limited. In newborns and infants with bleeding symptoms, APTT prolongation strongly suggests coagulation factor deficiency including hemophilia and should be followed by immediate FVIII activity measurement.
Diagnosis of hereditary factor VIII deficiency proceeds through a stepwise process of clinical history taking, coagulation screening tests, confirmation of FVIII activity, inhibitor testing, and molecular genetic confirmation. Accurate diagnosis is essential for treatment planning, assessment of inhibitor development risk, family counseling, and access to the latest gene therapies.
Clinical history and physical examination: Check a detailed bleeding history (whether spontaneous, site, duration, precipitating factors), family history (bleeding tendency among male relatives), and whether there was abnormal bleeding with past invasive procedures. Physical examination evaluates joint swelling, deformity, and contracture, bruising (ecchymosis), muscle hematomas, and mucosal bleeding findings. Using a standard bleeding assessment tool (ISTH Bleeding Assessment Tool, BAT), bleeding history can be systematically scored and used to screen for bleeding disorders such as hemophilia.
Coagulation screening tests: A pattern of prolonged APTT (activated partial thromboplastin time) with normal PT (prothrombin time), TT (thrombin time), fibrinogen, platelet count, and vWF is the typical finding of hemophilia A. In the APTT mixing study (1:1 mixing of patient plasma + normal plasma), correction of APTT suggests factor deficiency, and failure to correct suggests the presence of an inhibitor.
FVIII activity measurement: The key to diagnosis is measurement of FVIII clotting activity, and the one-stage clotting assay and two-stage chromogenic substrate assay are standard. The one-stage assay measures the degree of APTT shortening in FVIII-deficient plasma, and the chromogenic substrate assay measures the amount of FXa generated colorimetrically. Because results may be discrepant between the two methods (some mild hemophilia A, particularly the R593C variant), performing both methods is recommended when suspected. FVIII activity < 1 IU/dL (< 1%) is classified as severe, 1–5 IU/dL as moderate, and 5–40 IU/dL as mild.
vWF tests: FVIII deficiency must be differentiated from von Willebrand disease type 2N (Normandy). In vWD type 2N, the FVIII-binding capacity of vWF is reduced, so FVIII activity appears low. For differentiation, vWF antigen (VWF:Ag), vWF ristocetin cofactor activity (VWF:RCo or VWF:GPIbM), and vWF-FVIII binding assay (VWF:FVIIIB) need to be performed.
Inhibitor testing (Bethesda assay): Performed when response to treatment declines or bleeding persists despite standard FVIII replacement, or for regular screening after a certain exposure following confirmation of hemophilia A. Inhibitor titer is measured in Bethesda units (BU/mL) by the Bethesda assay or the standardized Nijmegen-modified Bethesda assay. 0.6 BU/mL or higher is judged positive, and inhibitors below 5 BU/mL are classified as low titer and 5 BU/mL or higher as high titer.
Molecular genetic confirmation: F8 gene variant analysis is used for predicting severity, assessing inhibitor development risk, family counseling, preimplantation/prenatal diagnosis, and determining eligibility for gene therapy. Intron 22 inversion and intron 1 inversion analysis are performed first, and if negative, NGS-based whole F8 gene analysis (exons + introns) is performed. When a variant is identified, it is shared for carrier testing of female family members.
Joint imaging evaluation: For diagnosis and follow-up of hemophilic arthropathy, X-ray (early bone changes, joint space narrowing), ultrasound (assessment of synovial thickness, effusion, angiogenesis; useful for rapid follow-up), and MRI (quantitative assessment of cartilage and bone structure, hemosiderin deposition, synoviocyte proliferation) are used complementarily. The standardized protocol of the hemophilia ultrasound expert group (HEAD-US) is widely used in clinical practice and research.
Treatment of hereditary factor VIII deficiency broadly consists of ① factor replacement therapy, ② non-factor therapy, ③ gene therapy, and ④ adjunctive treatment. The International Society on Thrombosis and Haemostasis (ISTH) 2024 clinical practice guideline and the World Federation of Hemophilia (WFH) 2020 guidelines strongly recommend prophylaxis over episodic treatment in severe hemophilia A.
Factor replacement therapy — FVIII concentrates: Plasma-derived (pd-FVIII) or recombinant (rFVIII) FVIII concentrates are the main treatment options. Standard half-life (SHL) rFVIII products have a half-life of about 8–12 hours and require prophylactic injections 3 times per week (every other day) or daily. Extended half-life (EHL) rFVIII products (efanesoctocog alfa, damoctocog alfa pegol, etc.) extend the half-life about 1.5–1.9-fold, providing equivalent prophylactic efficacy with administration 1–2 times per week, and efanesoctocog alfa (Alhemo/Altuviiio), launched in 2024, dissociates FVIII from vWF and greatly extends the half-life to about 37–42 hours. Prophylaxis is classified as primary (started before the first joint bleed or before age 2), secondary (started after a few joint damages), and tertiary (started after established arthropathy). FVIII target trough levels are trending upward from 1–3% to 10–15% or more, and pharmacokinetic (PK)-based individualized dosing is recommended.
Mild hemophilia A — desmopressin (DDAVP): In mild and some moderate patients with FVIII activity of 10 IU/dL or more, intravenous, subcutaneous, or intranasal DDAVP (desmopressin) administration can transiently raise endogenous FVIII 2–6-fold. Administration before minor surgery, tooth extraction, or examinations can reduce the need for FVIII replacement. With repeated administration, tachyphylaxis and hyponatremia should be watched for. It is standard to confirm responsiveness with a DDAVP response test before administration.
Antifibrinolytics: Tranexamic acid (TXA) or epsilon aminocaproic acid (EACA) is used adjunctively for bleeding of the oral mucosa, nasal cavity, and after dental procedures. They are used in combination with FVIII replacement therapy, or in mild hemophilia alone or combined with DDAVP. In urinary tract bleeding, caution is needed because of the risk of clot formation in the urinary tract.
Non-factor therapy — emicizumab (Hemlibra): A bispecific antibody that replaces FVIII, binding simultaneously to FIXa and FX to mimic intrinsic tenase-like activity. It is administered by subcutaneous injection (once weekly, once every other week, once every 4 weeks) and is effective regardless of inhibitor status. In the HAVEN 1–5 clinical trials, it was reported to reduce annual bleeding frequency by about 87–96%. The ISTH 2024 guideline strongly recommends emicizumab as prophylaxis in both severe patients with inhibitors and patients without inhibitors. Concomitant use of activated prothrombin complex concentrate (aPCC, FEIBA) during emicizumab administration carries a risk of thrombotic complications and requires careful judgment.
Non-factor therapy — fitusiran (Qfitlia): An RNAi therapy targeting antithrombin (AT) that suppresses AT expression to induce hemostatic rebalancing. With once-monthly subcutaneous injection, it can be used for both hemophilia A and B regardless of inhibitor status. It was approved by the FDA in March 2025 for adolescents aged 12 and over and adults. Monitoring for thrombotic risk is needed.
Inhibitor management — immune tolerance induction (ITI): The fundamental treatment strategy for patients who develop inhibitors, eliminating the inhibitor by continuously administering high-dose (50–200 IU/kg daily or every other day) or low-dose FVIII over a long period (months to years). The ITI success rate is about 60–80%, and predictors of success are a low-titer inhibitor, peak titer < 200 BU/mL, and early initiation. Acute bleeding after ITI failure or while waiting is treated with bypassing agents, recombinant activated FVIIa (rFVIIa, NovoSeven) or aPCC (FEIBA).
Gene therapy — valoctocogene roxaparvovec (Roctavian): A gene therapy that delivers a B-domain-deleted FVIII gene to hepatocytes using an AAV5 vector, aiming for sustained FVIII expression with a single intravenous injection. In the GENEr8-1 phase 3 clinical trial in adults with severe hemophilia A, annual bleeding frequency was reduced by 83.8%, and 3 years after administration 92% of patients remained off prophylaxis. Long-term follow-up is under way since FDA approval in 2022, and corticosteroid management of ALT elevation (abnormal liver enzyme levels) and the long-term durability of declining FVIII expression are important clinical challenges.
Adjunctive treatment and rehabilitation: In acute hemarthrosis, the PRICE (protection, rest, ice, compression, elevation) principle is applied together with FVIII injection. NSAIDs, aspirin, and antiplatelet agents are contraindicated because they increase bleeding risk by inhibiting platelet function; acetaminophen or COX-2 selective inhibitors are used instead. Physical therapy and rehabilitation (muscle strengthening, recovery of joint range of motion, balance training, aerobic exercise) are central to the prevention and management of hemophilic arthropathy. In advanced arthropathy, radiosynovectomy (radiosynoviorthesis, RSO), chemical synovectomy, arthroscopic synovectomy, or joint replacement (total knee replacement, etc.) is considered.
The prognosis of hemophilia A today has improved dramatically compared with decades ago. The life expectancy of patients managed with appropriate prophylaxis at multidisciplinary hemophilia treatment centers (HTCs) has improved to nearly the same level as the general population. The main factors affecting prognosis are severity, whether inhibitors develop, the degree of chronic arthropathy, history of bloodborne viral infection, and access to treatment.
Life expectancy and causes of death: In large cohort studies in developed countries, the life expectancy of patients with severe hemophilia A receiving prophylaxis is reported to show no statistically significant difference from unaffected males (about 73–77 years). As in the general population, cardiovascular disease and cancer rank highest among causes of death, and deaths from intracranial hemorrhage and associated bleeding have decreased markedly in HTC-managed patients. A study analyzing Korean National Health Insurance data also reported that survival of registered and treated patients has improved greatly.
Inhibitor development and prognosis: In about 25–30% of patients with severe hemophilia A, inhibitors develop after FVIII infusion, and this is the complication with the greatest negative impact on prognosis. Patients with inhibitors have difficulty with bleeding control, joint damage progresses rapidly, and quality of life declines. However, with the introduction of non-factor therapies such as emicizumab, the effectiveness of bleeding prevention has improved dramatically even in patients with inhibitors. After successful inhibitor elimination through ITI, standard prophylaxis can be resumed.
Hemophilic arthropathy: In severe patients who did not receive early primary prophylaxis, joint damage accumulated, and severe arthropathy (joint stiffness, muscle atrophy, gait abnormalities) developed in their 20s–30s. Under modern primary prophylaxis (started in infancy, maintaining target FVIII trough of 1–3% or more), a marked reduction in joint damage is reported, and in some studies the proportion of early primary prophylaxis patients maintaining normal joint function into adulthood exceeds 80%.
Prognosis of patients with HIV and HCV infection: Many patients who used non-virus-inactivated plasma-derived products in the 1970s–80s were coinfected with HIV and HCV and died. In surviving patients, liver cirrhosis and hepatocellular carcinoma due to chronic hepatitis C and HIV-related immunodeficiency remain important causes of morbidity and mortality. Antiviral treatment (direct-acting antivirals, DAAs) has made HCV cure possible, and active HCV treatment is recommended in these patients.
Long-term prognosis of gene therapy: AAV-based gene therapies such as valoctocogene roxaparvovec have made possible the elimination or dramatic reduction of bleeding for several years after administration. However, follow-up studies continue on the gradual decline in FVIII expression levels (especially after 2–5 years) and on long-term safety (hepatotoxicity, risk of insertional mutagenesis). The possibility of retreatment and immune responses in patients who have received gene therapy are also unresolved issues.
Follow-up: Hemophilia A patients are comprehensively evaluated regularly at hemophilia treatment centers (1–2 times per year for mild, 2–4 times for severe) for coagulation factor activity, inhibitors, joint status (HJHS, ultrasound, MRI), quality of life (Hemophilia-specific QoL tools), liver function, HIV and HCV status, and comorbidities. Patients registered under Korean Special Copayment Reduction V009 receive reduced copayment benefits for 5 years.
Prevention of hemophilia A is systematized into primary (prevention before occurrence), secondary (prevention of complications through early treatment), and tertiary (prevention of progression of complications that have already occurred) prevention. Complete primary prevention (preventing onset itself) is currently possible only through preimplantation and prenatal genetic diagnosis, and the most clinically important prevention is early prophylaxis, which is secondary prevention.
Primary prevention — genetic counseling and preimplantation/prenatal genetic testing: When a hemophilia A patient or a carrier woman plans to have children, the risks and options are discussed thoroughly with a hematologist and genetic counselor. Comprehensive counseling is needed, including the methods and limitations of F8 gene testing for carrier confirmation, prenatal diagnosis (CVS or amniocentesis), and preimplantation genetic testing (PGT), as well as ethical and religious considerations. When PGT is chosen, only unaffected embryos are implanted, theoretically allowing complete prevention of hemophilia in the child. However, because new (de novo) mutations can occur even without a family history, genetic counseling does not guarantee prevention in every case.
Secondary prevention — early primary prophylaxis: Primary prophylaxis started before the first joint bleed or before age 2 is the key strategy for minimizing joint damage. The WFH 2020 and ISTH 2024 guidelines strongly recommend prophylaxis instead of episodic treatment in severe hemophilia A. Regular prophylactic administration with FVIII concentrates (SHL or EHL) or emicizumab reduces bleeding frequency by up to 87–96%. Maintaining each patient's FVIII trough at target levels (minimum 1–3%, target 10–15% or more) with pharmacokinetics-based individualized dosing is the modern standard. Secondary prophylaxis is also considered in moderate and mild patients with recurrent bleeding.
Secondary prevention — infection prevention and hygiene: Because hemophilia patients may have an increased risk of bloodborne infection with intra-articular procedures or abscesses, vaccinations (influenza, pneumococcus, hepatitis B, hepatitis A, varicella, etc.) are kept up to date. Additional vaccination is recommended for those who have not developed hepatitis B antibodies. Completion of hepatitis A and B vaccination is essential for patients using plasma-derived products.
Tertiary prevention — joint protection and rehabilitation: Physical therapy and rehabilitation are essential to minimize ongoing joint damage. Low-impact exercise (swimming, cycling, walking) is recommended, and contact sports or high-risk activities are decided after individualized risk-benefit counseling. Because excess weight places additional load on joints, maintaining a healthy weight is recommended. Drugs that impair platelet function, such as NSAIDs and aspirin, must be avoided, and acetaminophen or COX-2 inhibitors are used first for pain management. For invasive procedures (surgery, tooth extraction, endoscopic biopsy, etc.), consult the hemophilia treatment center in advance and establish an FVIII replacement plan.
Emergency plans and patient education: All hemophilia A patients and caregivers should be familiar with how to self-inject FVIII in emergency bleeding situations, criteria for emergency room visits (suspected intracranial hemorrhage such as headache, neck stiffness, or altered consciousness; progression of muscle hematoma; suspected iliopsoas hematoma, etc.), always carrying a Medical Alert ID card, and the contact information of their hemophilia treatment center. It is recommended to inform schools, workplaces, and sports facilities of the patient's condition and share emergency response methods. Patient education programs and support services of the Korea Hemophilia Foundation and the Korean Society of Hemophilia should be actively used.
World Federation of Hemophilia. Guidelines for the Management of Haemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1-158. DOI: 10.1111/hae.14046
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1-158. PMID: 32744769.
Konkle BA, Skinner M, Iorio A. Hemophilia Trials: Cross-roads of Biology, Individual Patient Management, and Policy. J Thromb Haemost. 2024;22(8):2169-2183. DOI: 10.1016/j.jtha.2024.04.027
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors (HAVEN 1). N Engl J Med. 2017;377(9):809-818. DOI: 10.1056/NEJMoa1703068. PMID: 28691557.
Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A (GENEr8-1). N Engl J Med. 2020;382(1):29-40. DOI: 10.1056/NEJMoa1908490. PMID: 31893514.
Mannucci PM, Tuddenham EG. The hemophilias — from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779. DOI: 10.1056/NEJM200106073442307. PMID: 11396445.
Kim YU, Lim SJ, Jang MJ, et al. Complication Analysis in Korean Patients With Hemophilia A From 2007 to 2019: A Nationwide Study by the Health Insurance Review and Assessment Service Database. J Korean Med Sci. 2023;38(24):e235. DOI: 10.3346/jkms.2023.38.e235. PMID: 37402403.
Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019;104(9):1702-1709. DOI: 10.3324/haematol.2019.221093. PMID: 31413095.
Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12):2922-2934. DOI: 10.1182/blood-2011-09-380586. PMID: 22282501.
Dolan G, Benson G, Duffy A, et al. Hemophilia B: where are we now and what does the future hold? Blood Rev. 2018;32(1):52-60 (reference: comparison of F8/F9 genetic diagnosis and epidemiology). DOI: 10.1016/j.blre.2017.08.007. PMID: 28864361.